BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 18540933)

  • 1. Clinical practice experience with testosterone treatment in men with testosterone deficiency syndrome.
    McLaren D; Siemens DR; Izard J; Black A; Morales A
    BJU Int; 2008 Nov; 102(9):1142-6. PubMed ID: 18540933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.
    Morales A; Black AM; Emerson LE
    BJU Int; 2009 Jan; 103(1):62-4. PubMed ID: 18671790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL; Morgentaler A
    Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
    Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
    Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms.
    Leibowitz RL; Dorff TB; Tucker S; Symanowski J; Vogelzang NJ
    BJU Int; 2010 May; 105(10):1397-401. PubMed ID: 19912179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone replacement therapy after primary treatment for prostate cancer.
    Agarwal PK; Oefelein MG
    J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone supplementation does not worsen lower urinary tract symptoms.
    Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT
    J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial?
    Black AM; Day AG; Morales A
    BJU Int; 2004 Nov; 94(7):1066-70. PubMed ID: 15541129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone and the aging male: to treat or not to treat?
    Bain J
    Maturitas; 2010 May; 66(1):16-22. PubMed ID: 20153946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of testosterone replacement therapy following radical prostatectomy.
    Khera M; Lipshultz LI
    Urol Clin North Am; 2007 Nov; 34(4):549-53, vi. PubMed ID: 17983894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
    Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.
    Reyes-Vallejo L; Lazarou S; Morgentaler A
    J Sex Med; 2007 Nov; 4(6):1757-62. PubMed ID: 17087806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of one-year treatment with isoflavone extract from red clover on prostate, liver function, sexual function, and quality of life in men with elevated PSA levels and negative prostate biopsy findings.
    Engelhardt PF; Riedl CR
    Urology; 2008 Feb; 71(2):185-90; discussion 190. PubMed ID: 18308079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone replacement therapy and the risk of prostate cancer. Is there a link?
    Barqawi A; Crawford ED
    Int J Impot Res; 2006; 18(4):323-8. PubMed ID: 16281043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging.
    Cavallini G; Caracciolo S; Vitali G; Modenini F; Biagiotti G
    Urology; 2004 Apr; 63(4):641-6. PubMed ID: 15072869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Andropause. Testosterone replacement therapy for aging men.
    Bain J
    Can Fam Physician; 2001 Jan; 47():91-7. PubMed ID: 11212438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral testosterone replacement in Korean patients with PADAM.
    Hong JH; Ahn TY
    Aging Male; 2002 Mar; 5(1):52-6. PubMed ID: 12040976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.